{
  "abstract": "Cancer clinical trials form the foundation for the approval and use of new anticancer therapies. Alongside traditional endpoints such as survival and tumour response, patient-reported outcomes (PROs) are now a cornerstone of oncology trials and are increasingly expected by regulators.1 By capturing symptoms and functional health directly from patients, PROs provide essential information for patient-focused drug development and shared decision-making.",
  "authors": [
    {
      "affiliations": [
        "Health Outcomes Research Unit, University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria"
      ],
      "name": "Jens Lehmann"
    }
  ],
  "title": "Beyond the label: patient-reported outcomes and post-approval communication in oncology",
  "uid": "2174fe05-2989-5568-8252-231380f2965d"
}